Amphastar Pharmaceuticals (AMPH) FCF Margin (2013 - 2026)

Amphastar Pharmaceuticals' FCF Margin history runs 14 years deep, the most recent figure standing at 25.51% for Q1 2026.

• In Q1 2026, FCF Margin rose 917.0% year-over-year to 25.51%; the TTM figure through Mar 2026 stood at 22.79% (up 175.0% YoY), while the FY2025 annual figure was 20.61%, down 293.0% from the prior year.
• FCF Margin was 25.51% for Q1 2026 at Amphastar Pharmaceuticals, down from 28.25% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 39.02% in Q2 2024 to a low of 3.23% in Q2 2022.
• Historically, FCF Margin has averaged 21.28% across 5 years, with a median of 21.07% in 2025.
• The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 2898 bps in 2022, then jumped 2504 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 20.51% in 2022, then tumbled by 61 bps to 8.1% in 2023, then grew by 10 bps to 8.91% in 2024, then surged by 217 bps to 28.25% in 2025, then dropped by 10 bps to 25.51% in 2026.
• The last three FCF Margin figures came in at 25.51% (Q1 2026), 28.25% (Q4 2025), and 16.69% (Q3 2025), per Business Quant data.